JP2024521408A5 - - Google Patents
Info
- Publication number
- JP2024521408A5 JP2024521408A5 JP2023575753A JP2023575753A JP2024521408A5 JP 2024521408 A5 JP2024521408 A5 JP 2024521408A5 JP 2023575753 A JP2023575753 A JP 2023575753A JP 2023575753 A JP2023575753 A JP 2023575753A JP 2024521408 A5 JP2024521408 A5 JP 2024521408A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide chain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208514P | 2021-06-09 | 2021-06-09 | |
| US63/208,514 | 2021-06-09 | ||
| PCT/EP2022/065514 WO2022258673A1 (en) | 2021-06-09 | 2022-06-08 | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521408A JP2024521408A (ja) | 2024-05-31 |
| JP2024521408A5 true JP2024521408A5 (cg-RX-API-DMAC7.html) | 2025-06-16 |
Family
ID=82214258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575753A Pending JP2024521408A (ja) | 2021-06-09 | 2022-06-08 | Cd20、nkp46、cd16に結合し、かつil-2にコンジュゲートされた多特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002601A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4351733A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024521408A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240019786A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529504A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022288574A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025476A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227227A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308531A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014645A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022258673A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| KR20260081298A (ko) * | 2023-08-28 | 2026-06-02 | 젠코어 인코포레이티드 | 항-cd20 x 항-cd28 조합 요법 |
| TW202602921A (zh) * | 2024-02-09 | 2026-01-16 | 大陸商上海岸邁生物科技有限公司 | 多功能nk細胞接合器 |
| WO2026055280A1 (en) * | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1747237A4 (en) | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| KR20080032065A (ko) | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
| JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス,インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| US9598499B2 (en) | 2010-12-30 | 2017-03-21 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| RU2682449C2 (ru) | 2012-09-19 | 2019-03-19 | Иннейт Фарма | Связывающие kir3dl2 агенты |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
| CA3007898A1 (en) | 2015-12-28 | 2017-07-06 | Innate Pharma | Variable regions for nkp46 binding proteins |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| JP7778571B2 (ja) | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
| CA3143034A1 (en) | 2019-06-14 | 2020-12-17 | Cugene Inc. | Novel interleukin-2 variants for the treatment of cancer |
-
2022
- 2022-06-08 KR KR1020237045295A patent/KR20240019786A/ko active Pending
- 2022-06-08 IL IL308531A patent/IL308531A/en unknown
- 2022-06-08 AU AU2022288574A patent/AU2022288574A1/en active Pending
- 2022-06-08 JP JP2023575753A patent/JP2024521408A/ja active Pending
- 2022-06-08 CA CA3227227A patent/CA3227227A1/en active Pending
- 2022-06-08 US US18/568,806 patent/US20250002601A1/en active Pending
- 2022-06-08 WO PCT/EP2022/065514 patent/WO2022258673A1/en not_active Ceased
- 2022-06-08 MX MX2023014645A patent/MX2023014645A/es unknown
- 2022-06-08 BR BR112023025476A patent/BR112023025476A2/pt unknown
- 2022-06-08 CN CN202280041605.8A patent/CN117529504A/zh active Pending
- 2022-06-08 EP EP22733563.5A patent/EP4351733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Labriola-Tompkins et al. | Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor. | |
| Takatsu et al. | Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. | |
| Cherwinski et al. | Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. | |
| US20210269502A1 (en) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment | |
| Dumoutier et al. | IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes | |
| Brown et al. | B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells | |
| Wilson et al. | Clustering of cytokine genes on mouse chromosome 11. | |
| SE461223B (sv) | Mrna och cdna foer humant fibroblastinterferon, foerfarande foer deras framstaellning samt anvaendning daerav | |
| JPS63299A (ja) | ヒトg−csfタンパク質の発現 | |
| SE465223B (sv) | Moget rekombinant-humanleukocytinterferon och foerfarande foer dess framstaellning | |
| US11542318B2 (en) | Use of chemokine receptor CXCR5 | |
| Liu et al. | Mesenchymal stem cell-mediated immunomodulation of recruited mononuclear phagocytes during acute lung injury: a high-dimensional analysis study | |
| Chatchawan et al. | Oxynema, a new genus separated from the genus Phormidium (Cyanophyta) | |
| JPH03155795A (ja) | マウス・インターロイキン―6レセプター蛋白質 | |
| CN1193280A (zh) | 用于治疗的cd44基因表达的控制 | |
| CN116286844A (zh) | 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途 | |
| CN110684787B (zh) | 一种斑节对虾糖原合成酶激酶GSK3β基因及其应用 | |
| He et al. | Abundant members of Scavenger receptors family and their identification, characterization and expression against Vibrio alginolyticus infection in juvenile Larimichthys crocea | |
| CN1198186A (zh) | 趋化因子β-8的短形式 | |
| CN1040822A (zh) | 胃动素样多肽的制备及表达 | |
| CN107217068A (zh) | 一种提高重组犬干扰素‑α融合蛋白抗病毒活性的方法 | |
| Hattori et al. | The DNA sequence of human chromosome 21. | |
| CN115093476B (zh) | 花鲈II型干扰素IFN-γrel及其受体的抗病毒组合物和应用 | |
| Laskov et al. | Simultaneous expression of mu‐and gamma‐chain mRNA in cloned murine B‐lymphoma cell lines. | |
| Yasueda et al. | Effect of semi-random mutagenesis at the C-terminal 4 amino acids of human interleukin-6 on its biological activity |